[
  {
    "sentence": "On February 3, 2022, this literature search was updated in line with the review protocol (see Figure 1 and Supplementary Material) (12).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Funnel plots of all included studies were performed to assess publication bias (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nFlowsheet literature review and study selection for analysis. *n = 78 Correspond to multiple references to a single study, i.e., more than one journal article, clinicaltrials.gov and/or regulatory documents.FIGURE 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Of these 28 RCTs, 23 reported Pedi ACR 30/50/70 at any time point, while 9 parallel design studies reported Pedi ACR 30/50/70 3 months after treatment start (Figure 1 and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "There was high and statistically significant heterogeneity in the meta-analysis of all three ACR Pedi outcomes (I2 = 75% and p < 0.01 for ACR Pedi 30; I2 = 71% and p < 0.01 for ACR Pedi 50; and I2 = 58% and p = 0.01 for ACR Pedi 70) (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "ACR Pedi, American College of Rheumatology pediatric responses; eOJIA, extended oligoarticular juvenile idiopathic arthritis; ERA, enthesitis-related juvenile idiopathic arthritis; JIA, juvenile idiopathic arthritis; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drugs; PJIA, polyarticular juvenile idiopathic arthritis; PsA, psoriatic juvenile idiopathic arthritis; qw, every week; q2w, every 2 weeks; q4w, every 4 weeks; q6w, every 6 weeks; sJIA, systemic juvenile idiopathic arthritis; RR, risk ratio. #Compared against methotrexate monotherapy instead of placebo. $Weeks 0,2,6,q6w for ACUTE-JIA study and weeks 0,2,6 for CR004774 study. &8 mg/kg for > 30 kg, 12 mg/kg for < 30 kg for tocilizumab in TENDER study; 20 mg for < 30 kg, 40 mg for > 30 kg for adalimumab in the SYCAMORE study.The TENDER study lies outside the funnel plots (Figure 2) for all three ACR Pedi outcomes and contributes the most heterogeneity (data not shown).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In addition, tofacitinib showed superior efficacy vs. placebo in PJIA with RR = 1.45 (95% CI 1.12–1.87) (Figure 3A and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The pooled RR for Pedi ACR 30 was 1.42 (95% CI 1.11–1.81), indicating in general bDMARD therapy is significant superior compared to placebo or methotrexate (Figure 3A).Pedi ACR 50 and ACR 70\nSignificant treatment responses compared with placebo were observed for Pedi ACR 50 and Pedi ACR 70 in the same studies as for Pedi ACR 30 (Figures 1B,C and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The pooled RR for Pedi ACR 50 was 1.72 (95% CI 1.23–2.40) (Figure 3B) and for Pedi ACR 70 was 2.06 (95% CI 1.41–3.01) (Figure 3C).Systematic Review for Safety\nFigure 4 shows an overview of the frequency of overall AEs, overall infections, URTIs, and gastroenteritis in the 12 studies that reported ACR Pedi 30, 50, or 70 after 3 months of treatment.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Therefore, bDMARDs and JAK inhibitors in PJIA and various subgroups of JIA were compared for efficacy (ACR Pedi 30 RRs) against safety (RD) (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As an example, etanercept treatment in mixed JIA was associated with increased risk of any infection while increasing achievement of ACR Pedi 30 by ∼50% as compared to control arms (Figure 5B).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "In any case, a higher susceptibility to infections associated with bDMARDs or JAK inhibitors should be weighed against the therapeutic effects in children with JIA (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "To further illustrate this point, etanercept treatment in mixed JIA was associated with increased risk of any infection while increasing achievement of ACR Pedi 30 by ∼50% as compared to control arms (Figure 5B).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "On February 3, 2022, this literature search was updated in line with the review protocol (see Figure 1 and Supplementary Material) (12).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Funnel plots of all included studies were performed to assess publication bias (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nFlowsheet literature review and study selection for analysis. *n = 78 Correspond to multiple references to a single study, i.e., more than one journal article, clinicaltrials.gov and/or regulatory documents.FIGURE 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Of these 28 RCTs, 23 reported Pedi ACR 30/50/70 at any time point, while 9 parallel design studies reported Pedi ACR 30/50/70 3 months after treatment start (Figure 1 and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "There was high and statistically significant heterogeneity in the meta-analysis of all three ACR Pedi outcomes (I2 = 75% and p < 0.01 for ACR Pedi 30; I2 = 71% and p < 0.01 for ACR Pedi 50; and I2 = 58% and p = 0.01 for ACR Pedi 70) (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "ACR Pedi, American College of Rheumatology pediatric responses; eOJIA, extended oligoarticular juvenile idiopathic arthritis; ERA, enthesitis-related juvenile idiopathic arthritis; JIA, juvenile idiopathic arthritis; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drugs; PJIA, polyarticular juvenile idiopathic arthritis; PsA, psoriatic juvenile idiopathic arthritis; qw, every week; q2w, every 2 weeks; q4w, every 4 weeks; q6w, every 6 weeks; sJIA, systemic juvenile idiopathic arthritis; RR, risk ratio. #Compared against methotrexate monotherapy instead of placebo. $Weeks 0,2,6,q6w for ACUTE-JIA study and weeks 0,2,6 for CR004774 study. &8 mg/kg for > 30 kg, 12 mg/kg for < 30 kg for tocilizumab in TENDER study; 20 mg for < 30 kg, 40 mg for > 30 kg for adalimumab in the SYCAMORE study.The TENDER study lies outside the funnel plots (Figure 2) for all three ACR Pedi outcomes and contributes the most heterogeneity (data not shown).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In addition, tofacitinib showed superior efficacy vs. placebo in PJIA with RR = 1.45 (95% CI 1.12–1.87) (Figure 3A and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The pooled RR for Pedi ACR 30 was 1.42 (95% CI 1.11–1.81), indicating in general bDMARD therapy is significant superior compared to placebo or methotrexate (Figure 3A).Pedi ACR 50 and ACR 70\nSignificant treatment responses compared with placebo were observed for Pedi ACR 50 and Pedi ACR 70 in the same studies as for Pedi ACR 30 (Figures 1B,C and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The pooled RR for Pedi ACR 50 was 1.72 (95% CI 1.23–2.40) (Figure 3B) and for Pedi ACR 70 was 2.06 (95% CI 1.41–3.01) (Figure 3C).Systematic Review for Safety\nFigure 4 shows an overview of the frequency of overall AEs, overall infections, URTIs, and gastroenteritis in the 12 studies that reported ACR Pedi 30, 50, or 70 after 3 months of treatment.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Therefore, bDMARDs and JAK inhibitors in PJIA and various subgroups of JIA were compared for efficacy (ACR Pedi 30 RRs) against safety (RD) (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As an example, etanercept treatment in mixed JIA was associated with increased risk of any infection while increasing achievement of ACR Pedi 30 by ∼50% as compared to control arms (Figure 5B).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "In any case, a higher susceptibility to infections associated with bDMARDs or JAK inhibitors should be weighed against the therapeutic effects in children with JIA (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "To further illustrate this point, etanercept treatment in mixed JIA was associated with increased risk of any infection while increasing achievement of ACR Pedi 30 by ∼50% as compared to control arms (Figure 5B).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "On February 3, 2022, this literature search was updated in line with the review protocol (see Figure 1 and Supplementary Material) (12).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Funnel plots of all included studies were performed to assess publication bias (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nFlowsheet literature review and study selection for analysis. *n = 78 Correspond to multiple references to a single study, i.e., more than one journal article, clinicaltrials.gov and/or regulatory documents.FIGURE 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Of these 28 RCTs, 23 reported Pedi ACR 30/50/70 at any time point, while 9 parallel design studies reported Pedi ACR 30/50/70 3 months after treatment start (Figure 1 and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "There was high and statistically significant heterogeneity in the meta-analysis of all three ACR Pedi outcomes (I2 = 75% and p < 0.01 for ACR Pedi 30; I2 = 71% and p < 0.01 for ACR Pedi 50; and I2 = 58% and p = 0.01 for ACR Pedi 70) (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "ACR Pedi, American College of Rheumatology pediatric responses; eOJIA, extended oligoarticular juvenile idiopathic arthritis; ERA, enthesitis-related juvenile idiopathic arthritis; JIA, juvenile idiopathic arthritis; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drugs; PJIA, polyarticular juvenile idiopathic arthritis; PsA, psoriatic juvenile idiopathic arthritis; qw, every week; q2w, every 2 weeks; q4w, every 4 weeks; q6w, every 6 weeks; sJIA, systemic juvenile idiopathic arthritis; RR, risk ratio. #Compared against methotrexate monotherapy instead of placebo. $Weeks 0,2,6,q6w for ACUTE-JIA study and weeks 0,2,6 for CR004774 study. &8 mg/kg for > 30 kg, 12 mg/kg for < 30 kg for tocilizumab in TENDER study; 20 mg for < 30 kg, 40 mg for > 30 kg for adalimumab in the SYCAMORE study.The TENDER study lies outside the funnel plots (Figure 2) for all three ACR Pedi outcomes and contributes the most heterogeneity (data not shown).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In addition, tofacitinib showed superior efficacy vs. placebo in PJIA with RR = 1.45 (95% CI 1.12–1.87) (Figure 3A and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The pooled RR for Pedi ACR 30 was 1.42 (95% CI 1.11–1.81), indicating in general bDMARD therapy is significant superior compared to placebo or methotrexate (Figure 3A).Pedi ACR 50 and ACR 70\nSignificant treatment responses compared with placebo were observed for Pedi ACR 50 and Pedi ACR 70 in the same studies as for Pedi ACR 30 (Figures 1B,C and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The pooled RR for Pedi ACR 50 was 1.72 (95% CI 1.23–2.40) (Figure 3B) and for Pedi ACR 70 was 2.06 (95% CI 1.41–3.01) (Figure 3C).Systematic Review for Safety\nFigure 4 shows an overview of the frequency of overall AEs, overall infections, URTIs, and gastroenteritis in the 12 studies that reported ACR Pedi 30, 50, or 70 after 3 months of treatment.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Therefore, bDMARDs and JAK inhibitors in PJIA and various subgroups of JIA were compared for efficacy (ACR Pedi 30 RRs) against safety (RD) (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As an example, etanercept treatment in mixed JIA was associated with increased risk of any infection while increasing achievement of ACR Pedi 30 by ∼50% as compared to control arms (Figure 5B).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "In any case, a higher susceptibility to infections associated with bDMARDs or JAK inhibitors should be weighed against the therapeutic effects in children with JIA (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "To further illustrate this point, etanercept treatment in mixed JIA was associated with increased risk of any infection while increasing achievement of ACR Pedi 30 by ∼50% as compared to control arms (Figure 5B).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "On February 3, 2022, this literature search was updated in line with the review protocol (see Figure 1 and Supplementary Material) (12).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Funnel plots of all included studies were performed to assess publication bias (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nFlowsheet literature review and study selection for analysis. *n = 78 Correspond to multiple references to a single study, i.e., more than one journal article, clinicaltrials.gov and/or regulatory documents.FIGURE 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Of these 28 RCTs, 23 reported Pedi ACR 30/50/70 at any time point, while 9 parallel design studies reported Pedi ACR 30/50/70 3 months after treatment start (Figure 1 and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "There was high and statistically significant heterogeneity in the meta-analysis of all three ACR Pedi outcomes (I2 = 75% and p < 0.01 for ACR Pedi 30; I2 = 71% and p < 0.01 for ACR Pedi 50; and I2 = 58% and p = 0.01 for ACR Pedi 70) (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "ACR Pedi, American College of Rheumatology pediatric responses; eOJIA, extended oligoarticular juvenile idiopathic arthritis; ERA, enthesitis-related juvenile idiopathic arthritis; JIA, juvenile idiopathic arthritis; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drugs; PJIA, polyarticular juvenile idiopathic arthritis; PsA, psoriatic juvenile idiopathic arthritis; qw, every week; q2w, every 2 weeks; q4w, every 4 weeks; q6w, every 6 weeks; sJIA, systemic juvenile idiopathic arthritis; RR, risk ratio. #Compared against methotrexate monotherapy instead of placebo. $Weeks 0,2,6,q6w for ACUTE-JIA study and weeks 0,2,6 for CR004774 study. &8 mg/kg for > 30 kg, 12 mg/kg for < 30 kg for tocilizumab in TENDER study; 20 mg for < 30 kg, 40 mg for > 30 kg for adalimumab in the SYCAMORE study.The TENDER study lies outside the funnel plots (Figure 2) for all three ACR Pedi outcomes and contributes the most heterogeneity (data not shown).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In addition, tofacitinib showed superior efficacy vs. placebo in PJIA with RR = 1.45 (95% CI 1.12–1.87) (Figure 3A and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The pooled RR for Pedi ACR 30 was 1.42 (95% CI 1.11–1.81), indicating in general bDMARD therapy is significant superior compared to placebo or methotrexate (Figure 3A).Pedi ACR 50 and ACR 70\nSignificant treatment responses compared with placebo were observed for Pedi ACR 50 and Pedi ACR 70 in the same studies as for Pedi ACR 30 (Figures 1B,C and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The pooled RR for Pedi ACR 50 was 1.72 (95% CI 1.23–2.40) (Figure 3B) and for Pedi ACR 70 was 2.06 (95% CI 1.41–3.01) (Figure 3C).Systematic Review for Safety\nFigure 4 shows an overview of the frequency of overall AEs, overall infections, URTIs, and gastroenteritis in the 12 studies that reported ACR Pedi 30, 50, or 70 after 3 months of treatment.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Therefore, bDMARDs and JAK inhibitors in PJIA and various subgroups of JIA were compared for efficacy (ACR Pedi 30 RRs) against safety (RD) (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As an example, etanercept treatment in mixed JIA was associated with increased risk of any infection while increasing achievement of ACR Pedi 30 by ∼50% as compared to control arms (Figure 5B).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "In any case, a higher susceptibility to infections associated with bDMARDs or JAK inhibitors should be weighed against the therapeutic effects in children with JIA (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "To further illustrate this point, etanercept treatment in mixed JIA was associated with increased risk of any infection while increasing achievement of ACR Pedi 30 by ∼50% as compared to control arms (Figure 5B).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "On February 3, 2022, this literature search was updated in line with the review protocol (see Figure 1 and Supplementary Material) (12).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Funnel plots of all included studies were performed to assess publication bias (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nFlowsheet literature review and study selection for analysis. *n = 78 Correspond to multiple references to a single study, i.e., more than one journal article, clinicaltrials.gov and/or regulatory documents.FIGURE 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Of these 28 RCTs, 23 reported Pedi ACR 30/50/70 at any time point, while 9 parallel design studies reported Pedi ACR 30/50/70 3 months after treatment start (Figure 1 and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "There was high and statistically significant heterogeneity in the meta-analysis of all three ACR Pedi outcomes (I2 = 75% and p < 0.01 for ACR Pedi 30; I2 = 71% and p < 0.01 for ACR Pedi 50; and I2 = 58% and p = 0.01 for ACR Pedi 70) (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "ACR Pedi, American College of Rheumatology pediatric responses; eOJIA, extended oligoarticular juvenile idiopathic arthritis; ERA, enthesitis-related juvenile idiopathic arthritis; JIA, juvenile idiopathic arthritis; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drugs; PJIA, polyarticular juvenile idiopathic arthritis; PsA, psoriatic juvenile idiopathic arthritis; qw, every week; q2w, every 2 weeks; q4w, every 4 weeks; q6w, every 6 weeks; sJIA, systemic juvenile idiopathic arthritis; RR, risk ratio. #Compared against methotrexate monotherapy instead of placebo. $Weeks 0,2,6,q6w for ACUTE-JIA study and weeks 0,2,6 for CR004774 study. &8 mg/kg for > 30 kg, 12 mg/kg for < 30 kg for tocilizumab in TENDER study; 20 mg for < 30 kg, 40 mg for > 30 kg for adalimumab in the SYCAMORE study.The TENDER study lies outside the funnel plots (Figure 2) for all three ACR Pedi outcomes and contributes the most heterogeneity (data not shown).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In addition, tofacitinib showed superior efficacy vs. placebo in PJIA with RR = 1.45 (95% CI 1.12–1.87) (Figure 3A and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The pooled RR for Pedi ACR 30 was 1.42 (95% CI 1.11–1.81), indicating in general bDMARD therapy is significant superior compared to placebo or methotrexate (Figure 3A).Pedi ACR 50 and ACR 70\nSignificant treatment responses compared with placebo were observed for Pedi ACR 50 and Pedi ACR 70 in the same studies as for Pedi ACR 30 (Figures 1B,C and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The pooled RR for Pedi ACR 50 was 1.72 (95% CI 1.23–2.40) (Figure 3B) and for Pedi ACR 70 was 2.06 (95% CI 1.41–3.01) (Figure 3C).Systematic Review for Safety\nFigure 4 shows an overview of the frequency of overall AEs, overall infections, URTIs, and gastroenteritis in the 12 studies that reported ACR Pedi 30, 50, or 70 after 3 months of treatment.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Therefore, bDMARDs and JAK inhibitors in PJIA and various subgroups of JIA were compared for efficacy (ACR Pedi 30 RRs) against safety (RD) (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As an example, etanercept treatment in mixed JIA was associated with increased risk of any infection while increasing achievement of ACR Pedi 30 by ∼50% as compared to control arms (Figure 5B).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "In any case, a higher susceptibility to infections associated with bDMARDs or JAK inhibitors should be weighed against the therapeutic effects in children with JIA (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "To further illustrate this point, etanercept treatment in mixed JIA was associated with increased risk of any infection while increasing achievement of ACR Pedi 30 by ∼50% as compared to control arms (Figure 5B).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "On February 3, 2022, this literature search was updated in line with the review protocol (see Figure 1 and Supplementary Material) (12).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Funnel plots of all included studies were performed to assess publication bias (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nFlowsheet literature review and study selection for analysis. *n = 78 Correspond to multiple references to a single study, i.e., more than one journal article, clinicaltrials.gov and/or regulatory documents.FIGURE 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Of these 28 RCTs, 23 reported Pedi ACR 30/50/70 at any time point, while 9 parallel design studies reported Pedi ACR 30/50/70 3 months after treatment start (Figure 1 and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "There was high and statistically significant heterogeneity in the meta-analysis of all three ACR Pedi outcomes (I2 = 75% and p < 0.01 for ACR Pedi 30; I2 = 71% and p < 0.01 for ACR Pedi 50; and I2 = 58% and p = 0.01 for ACR Pedi 70) (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "ACR Pedi, American College of Rheumatology pediatric responses; eOJIA, extended oligoarticular juvenile idiopathic arthritis; ERA, enthesitis-related juvenile idiopathic arthritis; JIA, juvenile idiopathic arthritis; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drugs; PJIA, polyarticular juvenile idiopathic arthritis; PsA, psoriatic juvenile idiopathic arthritis; qw, every week; q2w, every 2 weeks; q4w, every 4 weeks; q6w, every 6 weeks; sJIA, systemic juvenile idiopathic arthritis; RR, risk ratio. #Compared against methotrexate monotherapy instead of placebo. $Weeks 0,2,6,q6w for ACUTE-JIA study and weeks 0,2,6 for CR004774 study. &8 mg/kg for > 30 kg, 12 mg/kg for < 30 kg for tocilizumab in TENDER study; 20 mg for < 30 kg, 40 mg for > 30 kg for adalimumab in the SYCAMORE study.The TENDER study lies outside the funnel plots (Figure 2) for all three ACR Pedi outcomes and contributes the most heterogeneity (data not shown).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In addition, tofacitinib showed superior efficacy vs. placebo in PJIA with RR = 1.45 (95% CI 1.12–1.87) (Figure 3A and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The pooled RR for Pedi ACR 30 was 1.42 (95% CI 1.11–1.81), indicating in general bDMARD therapy is significant superior compared to placebo or methotrexate (Figure 3A).Pedi ACR 50 and ACR 70\nSignificant treatment responses compared with placebo were observed for Pedi ACR 50 and Pedi ACR 70 in the same studies as for Pedi ACR 30 (Figures 1B,C and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The pooled RR for Pedi ACR 50 was 1.72 (95% CI 1.23–2.40) (Figure 3B) and for Pedi ACR 70 was 2.06 (95% CI 1.41–3.01) (Figure 3C).Systematic Review for Safety\nFigure 4 shows an overview of the frequency of overall AEs, overall infections, URTIs, and gastroenteritis in the 12 studies that reported ACR Pedi 30, 50, or 70 after 3 months of treatment.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Therefore, bDMARDs and JAK inhibitors in PJIA and various subgroups of JIA were compared for efficacy (ACR Pedi 30 RRs) against safety (RD) (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As an example, etanercept treatment in mixed JIA was associated with increased risk of any infection while increasing achievement of ACR Pedi 30 by ∼50% as compared to control arms (Figure 5B).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "In any case, a higher susceptibility to infections associated with bDMARDs or JAK inhibitors should be weighed against the therapeutic effects in children with JIA (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "To further illustrate this point, etanercept treatment in mixed JIA was associated with increased risk of any infection while increasing achievement of ACR Pedi 30 by ∼50% as compared to control arms (Figure 5B).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "On February 3, 2022, this literature search was updated in line with the review protocol (see Figure 1 and Supplementary Material) (12).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Funnel plots of all included studies were performed to assess publication bias (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nFlowsheet literature review and study selection for analysis. *n = 78 Correspond to multiple references to a single study, i.e., more than one journal article, clinicaltrials.gov and/or regulatory documents.FIGURE 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Of these 28 RCTs, 23 reported Pedi ACR 30/50/70 at any time point, while 9 parallel design studies reported Pedi ACR 30/50/70 3 months after treatment start (Figure 1 and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "There was high and statistically significant heterogeneity in the meta-analysis of all three ACR Pedi outcomes (I2 = 75% and p < 0.01 for ACR Pedi 30; I2 = 71% and p < 0.01 for ACR Pedi 50; and I2 = 58% and p = 0.01 for ACR Pedi 70) (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "ACR Pedi, American College of Rheumatology pediatric responses; eOJIA, extended oligoarticular juvenile idiopathic arthritis; ERA, enthesitis-related juvenile idiopathic arthritis; JIA, juvenile idiopathic arthritis; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drugs; PJIA, polyarticular juvenile idiopathic arthritis; PsA, psoriatic juvenile idiopathic arthritis; qw, every week; q2w, every 2 weeks; q4w, every 4 weeks; q6w, every 6 weeks; sJIA, systemic juvenile idiopathic arthritis; RR, risk ratio. #Compared against methotrexate monotherapy instead of placebo. $Weeks 0,2,6,q6w for ACUTE-JIA study and weeks 0,2,6 for CR004774 study. &8 mg/kg for > 30 kg, 12 mg/kg for < 30 kg for tocilizumab in TENDER study; 20 mg for < 30 kg, 40 mg for > 30 kg for adalimumab in the SYCAMORE study.The TENDER study lies outside the funnel plots (Figure 2) for all three ACR Pedi outcomes and contributes the most heterogeneity (data not shown).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In addition, tofacitinib showed superior efficacy vs. placebo in PJIA with RR = 1.45 (95% CI 1.12–1.87) (Figure 3A and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The pooled RR for Pedi ACR 30 was 1.42 (95% CI 1.11–1.81), indicating in general bDMARD therapy is significant superior compared to placebo or methotrexate (Figure 3A).Pedi ACR 50 and ACR 70\nSignificant treatment responses compared with placebo were observed for Pedi ACR 50 and Pedi ACR 70 in the same studies as for Pedi ACR 30 (Figures 1B,C and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The pooled RR for Pedi ACR 50 was 1.72 (95% CI 1.23–2.40) (Figure 3B) and for Pedi ACR 70 was 2.06 (95% CI 1.41–3.01) (Figure 3C).Systematic Review for Safety\nFigure 4 shows an overview of the frequency of overall AEs, overall infections, URTIs, and gastroenteritis in the 12 studies that reported ACR Pedi 30, 50, or 70 after 3 months of treatment.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Therefore, bDMARDs and JAK inhibitors in PJIA and various subgroups of JIA were compared for efficacy (ACR Pedi 30 RRs) against safety (RD) (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As an example, etanercept treatment in mixed JIA was associated with increased risk of any infection while increasing achievement of ACR Pedi 30 by ∼50% as compared to control arms (Figure 5B).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "In any case, a higher susceptibility to infections associated with bDMARDs or JAK inhibitors should be weighed against the therapeutic effects in children with JIA (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "To further illustrate this point, etanercept treatment in mixed JIA was associated with increased risk of any infection while increasing achievement of ACR Pedi 30 by ∼50% as compared to control arms (Figure 5B).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "On February 3, 2022, this literature search was updated in line with the review protocol (see Figure 1 and Supplementary Material) (12).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Funnel plots of all included studies were performed to assess publication bias (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nFlowsheet literature review and study selection for analysis. *n = 78 Correspond to multiple references to a single study, i.e., more than one journal article, clinicaltrials.gov and/or regulatory documents.FIGURE 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Of these 28 RCTs, 23 reported Pedi ACR 30/50/70 at any time point, while 9 parallel design studies reported Pedi ACR 30/50/70 3 months after treatment start (Figure 1 and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "There was high and statistically significant heterogeneity in the meta-analysis of all three ACR Pedi outcomes (I2 = 75% and p < 0.01 for ACR Pedi 30; I2 = 71% and p < 0.01 for ACR Pedi 50; and I2 = 58% and p = 0.01 for ACR Pedi 70) (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "ACR Pedi, American College of Rheumatology pediatric responses; eOJIA, extended oligoarticular juvenile idiopathic arthritis; ERA, enthesitis-related juvenile idiopathic arthritis; JIA, juvenile idiopathic arthritis; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drugs; PJIA, polyarticular juvenile idiopathic arthritis; PsA, psoriatic juvenile idiopathic arthritis; qw, every week; q2w, every 2 weeks; q4w, every 4 weeks; q6w, every 6 weeks; sJIA, systemic juvenile idiopathic arthritis; RR, risk ratio. #Compared against methotrexate monotherapy instead of placebo. $Weeks 0,2,6,q6w for ACUTE-JIA study and weeks 0,2,6 for CR004774 study. &8 mg/kg for > 30 kg, 12 mg/kg for < 30 kg for tocilizumab in TENDER study; 20 mg for < 30 kg, 40 mg for > 30 kg for adalimumab in the SYCAMORE study.The TENDER study lies outside the funnel plots (Figure 2) for all three ACR Pedi outcomes and contributes the most heterogeneity (data not shown).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In addition, tofacitinib showed superior efficacy vs. placebo in PJIA with RR = 1.45 (95% CI 1.12–1.87) (Figure 3A and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The pooled RR for Pedi ACR 30 was 1.42 (95% CI 1.11–1.81), indicating in general bDMARD therapy is significant superior compared to placebo or methotrexate (Figure 3A).Pedi ACR 50 and ACR 70\nSignificant treatment responses compared with placebo were observed for Pedi ACR 50 and Pedi ACR 70 in the same studies as for Pedi ACR 30 (Figures 1B,C and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The pooled RR for Pedi ACR 50 was 1.72 (95% CI 1.23–2.40) (Figure 3B) and for Pedi ACR 70 was 2.06 (95% CI 1.41–3.01) (Figure 3C).Systematic Review for Safety\nFigure 4 shows an overview of the frequency of overall AEs, overall infections, URTIs, and gastroenteritis in the 12 studies that reported ACR Pedi 30, 50, or 70 after 3 months of treatment.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Therefore, bDMARDs and JAK inhibitors in PJIA and various subgroups of JIA were compared for efficacy (ACR Pedi 30 RRs) against safety (RD) (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As an example, etanercept treatment in mixed JIA was associated with increased risk of any infection while increasing achievement of ACR Pedi 30 by ∼50% as compared to control arms (Figure 5B).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "In any case, a higher susceptibility to infections associated with bDMARDs or JAK inhibitors should be weighed against the therapeutic effects in children with JIA (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "To further illustrate this point, etanercept treatment in mixed JIA was associated with increased risk of any infection while increasing achievement of ACR Pedi 30 by ∼50% as compared to control arms (Figure 5B).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "On February 3, 2022, this literature search was updated in line with the review protocol (see Figure 1 and Supplementary Material) (12).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Funnel plots of all included studies were performed to assess publication bias (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nFlowsheet literature review and study selection for analysis. *n = 78 Correspond to multiple references to a single study, i.e., more than one journal article, clinicaltrials.gov and/or regulatory documents.FIGURE 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On February 3, 2022, this literature search was updated in line with the review protocol (see Figure 1 and Supplementary Material) (12).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Funnel plots of all included studies were performed to assess publication bias (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Open in a new tab\nFlowsheet literature review and study selection for analysis. *n = 78 Correspond to multiple references to a single study, i.e., more than one journal article, clinicaltrials.gov and/or regulatory documents.FIGURE 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "On February 3, 2022, this literature search was updated in line with the review protocol (see Figure 1 and Supplementary Material) (12).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Funnel plots of all included studies were performed to assess publication bias (Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Of these 28 RCTs, 23 reported Pedi ACR 30/50/70 at any time point, while 9 parallel design studies reported Pedi ACR 30/50/70 3 months after treatment start (Figure 1 and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "There was high and statistically significant heterogeneity in the meta-analysis of all three ACR Pedi outcomes (I2 = 75% and p < 0.01 for ACR Pedi 30; I2 = 71% and p < 0.01 for ACR Pedi 50; and I2 = 58% and p = 0.01 for ACR Pedi 70) (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "ACR Pedi, American College of Rheumatology pediatric responses; eOJIA, extended oligoarticular juvenile idiopathic arthritis; ERA, enthesitis-related juvenile idiopathic arthritis; JIA, juvenile idiopathic arthritis; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drugs; PJIA, polyarticular juvenile idiopathic arthritis; PsA, psoriatic juvenile idiopathic arthritis; qw, every week; q2w, every 2 weeks; q4w, every 4 weeks; q6w, every 6 weeks; sJIA, systemic juvenile idiopathic arthritis; RR, risk ratio. #Compared against methotrexate monotherapy instead of placebo. $Weeks 0,2,6,q6w for ACUTE-JIA study and weeks 0,2,6 for CR004774 study. &8 mg/kg for > 30 kg, 12 mg/kg for < 30 kg for tocilizumab in TENDER study; 20 mg for < 30 kg, 40 mg for > 30 kg for adalimumab in the SYCAMORE study.The TENDER study lies outside the funnel plots (Figure 2) for all three ACR Pedi outcomes and contributes the most heterogeneity (data not shown).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In addition, tofacitinib showed superior efficacy vs. placebo in PJIA with RR = 1.45 (95% CI 1.12–1.87) (Figure 3A and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The pooled RR for Pedi ACR 30 was 1.42 (95% CI 1.11–1.81), indicating in general bDMARD therapy is significant superior compared to placebo or methotrexate (Figure 3A).Pedi ACR 50 and ACR 70\nSignificant treatment responses compared with placebo were observed for Pedi ACR 50 and Pedi ACR 70 in the same studies as for Pedi ACR 30 (Figures 1B,C and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The pooled RR for Pedi ACR 50 was 1.72 (95% CI 1.23–2.40) (Figure 3B) and for Pedi ACR 70 was 2.06 (95% CI 1.41–3.01) (Figure 3C).Systematic Review for Safety\nFigure 4 shows an overview of the frequency of overall AEs, overall infections, URTIs, and gastroenteritis in the 12 studies that reported ACR Pedi 30, 50, or 70 after 3 months of treatment.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Therefore, bDMARDs and JAK inhibitors in PJIA and various subgroups of JIA were compared for efficacy (ACR Pedi 30 RRs) against safety (RD) (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As an example, etanercept treatment in mixed JIA was associated with increased risk of any infection while increasing achievement of ACR Pedi 30 by ∼50% as compared to control arms (Figure 5B).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Of these 28 RCTs, 23 reported Pedi ACR 30/50/70 at any time point, while 9 parallel design studies reported Pedi ACR 30/50/70 3 months after treatment start (Figure 1 and Table 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "There was high and statistically significant heterogeneity in the meta-analysis of all three ACR Pedi outcomes (I2 = 75% and p < 0.01 for ACR Pedi 30; I2 = 71% and p < 0.01 for ACR Pedi 50; and I2 = 58% and p = 0.01 for ACR Pedi 70) (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "ACR Pedi, American College of Rheumatology pediatric responses; eOJIA, extended oligoarticular juvenile idiopathic arthritis; ERA, enthesitis-related juvenile idiopathic arthritis; JIA, juvenile idiopathic arthritis; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drugs; PJIA, polyarticular juvenile idiopathic arthritis; PsA, psoriatic juvenile idiopathic arthritis; qw, every week; q2w, every 2 weeks; q4w, every 4 weeks; q6w, every 6 weeks; sJIA, systemic juvenile idiopathic arthritis; RR, risk ratio. #Compared against methotrexate monotherapy instead of placebo. $Weeks 0,2,6,q6w for ACUTE-JIA study and weeks 0,2,6 for CR004774 study. &8 mg/kg for > 30 kg, 12 mg/kg for < 30 kg for tocilizumab in TENDER study; 20 mg for < 30 kg, 40 mg for > 30 kg for adalimumab in the SYCAMORE study.The TENDER study lies outside the funnel plots (Figure 2) for all three ACR Pedi outcomes and contributes the most heterogeneity (data not shown).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In addition, tofacitinib showed superior efficacy vs. placebo in PJIA with RR = 1.45 (95% CI 1.12–1.87) (Figure 3A and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The pooled RR for Pedi ACR 30 was 1.42 (95% CI 1.11–1.81), indicating in general bDMARD therapy is significant superior compared to placebo or methotrexate (Figure 3A).Pedi ACR 50 and ACR 70\nSignificant treatment responses compared with placebo were observed for Pedi ACR 50 and Pedi ACR 70 in the same studies as for Pedi ACR 30 (Figures 1B,C and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The pooled RR for Pedi ACR 50 was 1.72 (95% CI 1.23–2.40) (Figure 3B) and for Pedi ACR 70 was 2.06 (95% CI 1.41–3.01) (Figure 3C).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "There was high and statistically significant heterogeneity in the meta-analysis of all three ACR Pedi outcomes (I2 = 75% and p < 0.01 for ACR Pedi 30; I2 = 71% and p < 0.01 for ACR Pedi 50; and I2 = 58% and p = 0.01 for ACR Pedi 70) (Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The TENDER study lies outside the funnel plots (Figure 2) for all three ACR Pedi outcomes and contributes the most heterogeneity (data not shown).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "In addition, tofacitinib showed superior efficacy vs. placebo in PJIA with RR = 1.45 (95% CI 1.12–1.87) (Figure 3A and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The pooled RR for Pedi ACR 30 was 1.42 (95% CI 1.11–1.81), indicating in general bDMARD therapy is significant superior compared to placebo or methotrexate (Figure 3A).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "In addition, tofacitinib showed superior efficacy vs. placebo in PJIA with RR = 1.45 (95% CI 1.12–1.87) (Figure 3A and Table 2).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The pooled RR for Pedi ACR 30 was 1.42 (95% CI 1.11–1.81), indicating in general bDMARD therapy is significant superior compared to placebo or methotrexate (Figure 3A).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The pooled RR for Pedi ACR 50 was 1.72 (95% CI 1.23–2.40) (Figure 3B) and for Pedi ACR 70 was 2.06 (95% CI 1.41–3.01) (Figure 3C).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "The pooled RR for Pedi ACR 50 was 1.72 (95% CI 1.23–2.40) (Figure 3B) and for Pedi ACR 70 was 2.06 (95% CI 1.41–3.01) (Figure 3C).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel B",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Systematic Review for Safety\nFigure 4 shows an overview of the frequency of overall AEs, overall infections, URTIs, and gastroenteritis in the 12 studies that reported ACR Pedi 30, 50, or 70 after 3 months of treatment.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Therefore, bDMARDs and JAK inhibitors in PJIA and various subgroups of JIA were compared for efficacy (ACR Pedi 30 RRs) against safety (RD) (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As an example, etanercept treatment in mixed JIA was associated with increased risk of any infection while increasing achievement of ACR Pedi 30 by ∼50% as compared to control arms (Figure 5B).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Figure 4 shows an overview of the frequency of overall AEs, overall infections, URTIs, and gastroenteritis in the 12 studies that reported ACR Pedi 30, 50, or 70 after 3 months of treatment.",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "Therefore, bDMARDs and JAK inhibitors in PJIA and various subgroups of JIA were compared for efficacy (ACR Pedi 30 RRs) against safety (RD) (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "As an example, etanercept treatment in mixed JIA was associated with increased risk of any infection while increasing achievement of ACR Pedi 30 by ∼50% as compared to control arms (Figure 5B).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "In any case, a higher susceptibility to infections associated with bDMARDs or JAK inhibitors should be weighed against the therapeutic effects in children with JIA (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "To further illustrate this point, etanercept treatment in mixed JIA was associated with increased risk of any infection while increasing achievement of ACR Pedi 30 by ∼50% as compared to control arms (Figure 5B).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "In any case, a higher susceptibility to infections associated with bDMARDs or JAK inhibitors should be weighed against the therapeutic effects in children with JIA (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "To further illustrate this point, etanercept treatment in mixed JIA was associated with increased risk of any infection while increasing achievement of ACR Pedi 30 by ∼50% as compared to control arms (Figure 5B).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "In any case, a higher susceptibility to infections associated with bDMARDs or JAK inhibitors should be weighed against the therapeutic effects in children with JIA (Figure 5).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "To further illustrate this point, etanercept treatment in mixed JIA was associated with increased risk of any infection while increasing achievement of ACR Pedi 30 by ∼50% as compared to control arms (Figure 5B).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel B",
        "figure_key": "figure_5"
      }
    ]
  }
]